News
01-06-2011, 09:31 PM
MacroGenics, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical trial of MGAH22.
More... (http://www.news-medical.net/news/20110106/MacroGenics-commences-MGAH22-Phase-I-trail-for-patients-with-HER2-positive-cancer.aspx)
More... (http://www.news-medical.net/news/20110106/MacroGenics-commences-MGAH22-Phase-I-trail-for-patients-with-HER2-positive-cancer.aspx)